Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001734 Act: 34 Size: 7 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001732 Act: 34 Size: 224 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001472 Act: 34 Size: 132 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001124 Act: 34 Size: 14 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-000979 Act: 34 Size: 17 KB 网页链接
$Sol-gel(SLGL)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-21-000909 Act: 34 Size: 6 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-000907 Act: 34 Size: 232 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-000813 Act: 34 Size: 4 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-000683 Act: 34 Size: 293 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-21-000460 Act: 34 Size: 87 KB 网页链接